Ignyta (RXDX) Announces Encouraging RXDX-105 Phase 1/1b Data; ORR of 56% Noted
Tweet Send to a Friend
Ignyta, Inc. (Nasdaq: RXDX) announced data from an ongoing Phase 1/1b study of RXDX-105—Ignyta’s VEGFR-sparing, potent RET inhibitor—at the 2016 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
